EntreMed to Present at the Rodman and Renshaw 9th Annual Healthcare Conference

ROCKVILLE, Md., Oct. 31 /PRNewswire-FirstCall/ — EntreMed, Inc. a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced today that James S. Burns, President and Chief Executive Officer, will present a Company overview at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference, to be held at the New York Palace Hotel in New York, November 5-7, 2007. Mr. Burns’ presentation is scheduled for Tuesday, November 6, 2007 at 10:15 a.m. (local time).

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

Mr. Burns’ live presentation will be web cast and can be accessed through the Company’s web site at http://www.entremed.com/. An archive will be available on the web site for approximately 90 days.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. Panzem(R) NCD (2-methoxyestradiol or 2ME2) is currently in multiple Phase 2 clinical trials for cancer. MKC-1, an oral cell-cycle regulator, is in multiple Phase 1 and 2 studies for cancer. ENMD-1198, a novel tubulin-binding agent, is in Phase 1 studies in advanced cancers. Panzem(R) is also in preclinical development for rheumatoid arthritis, and ENMD-2076, a dual-acting Aurora-angiogenesis inhibitor, is in preclinical development for cancer. EntreMed’s goal is to develop and commercialize new compounds based on the Company’s expertise in angiogenesis, cell-cycle regulation and inflammation — processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company’s web site at http://www.entremed.com/ and in various filings with the Securities and Exchange Commission.

    CONTACT:    Ginny Dunn    Associate Director    Corporate Communications &    Investor Relations    EntreMed, Inc.    240-864-2643  

Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGOAP Archive: http://photoarchive.ap.org/PRN Photo Desk, photodesk@prnewswire.com

EntreMed, Inc.

CONTACT: Ginny Dunn, Associate Director, Corporate Communications &Investor Relations of EntreMed, Inc., +1-240-864-2643

Web site: http://www.entremed.com/